Trial · NCT07490990
Disitamab Vedotin Combined With Sintilimab and Multimodal Radiotherapy for HER2-Positive Advanced Gastric Cancer After Second-Line Treatment Failure: A Prospective, Single-Arm Phase II Clinical Trial
NCT07490990, Phase 2, Not yet recruiting, West China Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Disitamab Vedotin Combined With Sintilimab and Multimodal Radiotherapy for HER2-Positive Advanced Gastric Cancer After Second-Line Treatment Failure: A Prospective, Single-Arm Phase II Clinical Trial. Trials, record NCT07490990. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07490990
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Disitamab Vedotin Combined With Sintilimab and Multimodal Radiotherapy for HER2-Positive Advanced Gastric Cancer After Second-Line Treatment Failure: A Prospective, Single-Arm Phase II Clinical Trial
- NCT number
- NCT07490990
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 30 participants, estimated
- Lead sponsor
- West China Hospital
- Conditions
- HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
- Interventions
- Disitamab vedotin + Sintilimab + Multimodality radiotherapy
- First posted
- 2026-03-24
- Last updated
- 2026-08-03
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) | Up to 24 months from enrollment of the last participant | Time from study enrollment to documented disease progression (per RECIST v1.1) or death from any cause, whichever occurs first. Patients without progression or death will be censored at the last valid tumor assessment. |
| Secondary | Objective Response Rate (ORR) | Up to 24 months from enrollment of the last participant | Percentage of participants achieving confirmed complete response (CR) or partial response (PR) according to RECIST v1.1. |
| Secondary | Disease Control Rate (DCR) | Up to 24 months from enrollment of the last participant | Percentage of participants achieving confirmed CR, PR, or stable disease (SD) according to RECIST v1.1. |
| Secondary | Overall Survival (OS) | Up to 36 months from enrollment of the last participant | Time from study enrollment to death from any cause. Participants alive at data cutoff will be censored at the last follow-up date |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07490990
GET https://conductscience.org/api/trials/v1/NCT07490990/registered